BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30036609)

  • 1. Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
    Qiu H; Zmina PM; Huang AY; Askew D; Bedogni B
    Cancer Lett; 2018 Oct; 434():144-151. PubMed ID: 30036609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
    Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1.
    Yang Z; Qi Y; Lai N; Zhang J; Chen Z; Liu M; Zhang W; Luo R; Kang S
    J Exp Clin Cancer Res; 2018 Jan; 37(1):1. PubMed ID: 29301578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
    Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.
    Medrano RF; Catani JP; Ribeiro AH; Tomaz SL; Merkel CA; Costanzi-Strauss E; Strauss BE
    Cancer Immunol Immunother; 2016 Apr; 65(4):371-82. PubMed ID: 26887933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-1α Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma.
    Singh S; Xiao Z; Bavisi K; Roszik J; Melendez BD; Wang Z; Cantwell MJ; Davis RE; Lizee G; Hwu P; Neelapu SS; Overwijk WW; Singh M
    J Immunol; 2021 Apr; 206(8):1966-1975. PubMed ID: 33722878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
    Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
    J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
    Shrimali R; Ahmad S; Berrong Z; Okoev G; Matevosyan A; Razavi GSE; Petit R; Gupta S; Mkrtichyan M; Khleif SN
    J Immunother Cancer; 2017 Aug; 5(1):64. PubMed ID: 28807056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
    Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
    Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic DNA vaccine targeting Foxp3
    Namdar A; Mirzaei R; Memarnejadian A; Boghosian R; Samadi M; Mirzaei HR; Farajifard H; Zavar M; Azadmanesh K; Elahi S; Noorbakhsh F; Rezaei A; Hadjati J
    Cancer Immunol Immunother; 2018 Mar; 67(3):367-379. PubMed ID: 29124314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
    Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
    Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
    Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
    Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Anti-melanoma Efficacy of a Pim-3-Targeting Bifunctional Small Hairpin RNA via Single-Stranded RNA-Mediated Activation of Plasmacytoid Dendritic Cells.
    Liu J; Hu Y; Guo Q; Yu X; Shao L; Zhang C
    Front Immunol; 2019; 10():2721. PubMed ID: 31849942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer.
    Tao Z; McCall NS; Wiedemann N; Vuagniaux G; Yuan Z; Lu B
    Clin Cancer Res; 2019 Feb; 25(3):1113-1124. PubMed ID: 30352911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycyrrhizic acid facilitates anti-tumor immunity by attenuating Tregs and MDSCs: An immunotherapeutic approach.
    Juin SK; Ghosh S; Majumdar S
    Int Immunopharmacol; 2020 Nov; 88():106932. PubMed ID: 32890791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
    Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
    Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting myeloid-derived suppressive cells in the tumor microenvironment to enhance the efficacy of cancer immunotherapy.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2020; 30(161):119-128. PubMed ID: 33593480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.